Banque Pictet & Cie SA boosted its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 9.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,544 shares of the biotechnology company's stock after acquiring an additional 2,152 shares during the period. Banque Pictet & Cie SA's holdings in Repligen were worth $3,123,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC increased its holdings in shares of Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after purchasing an additional 191,439 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its holdings in Repligen by 3.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock valued at $124,727,000 after acquiring an additional 32,665 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Repligen Stock Up 3.2%
Shares of NASDAQ RGEN traded up $4.18 during trading hours on Thursday, hitting $134.00. The stock had a trading volume of 545,221 shares, compared to its average volume of 725,807. The company has a market capitalization of $7.53 billion, a P/E ratio of -297.78, a P/E/G ratio of 3.68 and a beta of 1.11. The firm's 50-day moving average price is $125.88 and its two-hundred day moving average price is $139.50. Repligen Corporation has a 52 week low of $102.97 and a 52 week high of $182.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same quarter in the prior year, the business earned $0.28 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. Analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Barclays assumed coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target for the company. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Evercore ISI lowered their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group dropped their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and an average target price of $170.75.
View Our Latest Analysis on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
